A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (RESPOND) | Zendy

João Figueira | Zendy; José Henriques | Zendy; Miguel Amaro | Zendy; Vítor Rosas | Zendy; Dalila Alves | Zendy; José CunhaVaz | Zendy

Open Access

A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (RESPOND)

Author(s) -

João Figueira,

José Henriques,

Miguel Amaro,

Vítor Rosas,

Dalila Alves,

José CunhaVaz

Publication year - 2017

Publication title -

ophthalmic research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.893

H-Index - 54

eISSN - 1423-0259

pISSN - 0030-3747

DOI - 10.1159/000455235

Subject(s) - medicine , diabetic macular edema , edema , open label , macular edema , diabetes mellitus , multicenter study , ophthalmology , diabetic retinopathy , intensive care medicine , surgery , clinical trial , visual acuity , randomized controlled trial , endocrinology

The aim of this study was to assess the effectiveness and safety of ILUVIEN® in patients with chronic diabetic macular edema (DME) who were insufficiently responsive to prior therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research